IMI Funding rules set to change to benefit SMEs and biotechs
This article was originally published in Scrip
Executive Summary
The €2 billion European Commission-EFPIA backed Innovative Medicines Initiative (IMI) will be changing its funding rules to benefit SMEs, biotech firms and universities, after these bodies criticised the IMI's lack of alignment with FP7 rules which had worked against them.